CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

BioVie stock sinks on Phase IIb Parkinson’s trial data

Phase 2negativeNegative
AI Analysis

Summary

BioVie's stock declined following negative Phase IIb trial data for its Parkinson's disease candidate. The trial did not meet its primary endpoints.

Clinical Trial Data

Phase

IIb

Primary Endpoint

Not Met

Importance:7/10
Sentiment:
-0.80
Phase IIbParkinson's diseaseclinical trial datanegative results
Related Companies

Read the original article

Published by yahoo_finance on August 7, 2026 11:05 AM

Read Original